OncoMatch/Clinical Trials/NCT07139990
Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
Is NCT07139990 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies non-drug interventions for small cell lung cancer extensive stage.
To characterize feasibility, safety, and/or preliminary efficacy of personalized strategies to adapt standard radiotherapy treatments to individual patient responses.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Tumor Agnostic
Disease stage
Required: Stage IV
Extensive stage small cell lung cancer diagnosed by tissue biopsy within 180 days of registration.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemoimmunotherapy — standard of care
Patient must be planned for or receiving standard of care chemoimmunotherapy. Patient must have received no more than 3 cycles by time of study enrollment.
Cannot have received: thoracic radiotherapy
Prior thoracic Radiotherapy
Cannot have received: whole brain radiotherapy
Prior whole brain Radiotherapy
Cannot have received: surgical resection or focal radiotherapy of a target brain metastasis
Prior surgical resection or focal radiotherapy of a target brain metastasis
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Ut Southwestern Medical Center · Dallas, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify